Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...

PR NewswireJul 10 09:10 ET

10-Q: Quarterly report

SEC announcementMay 20 17:33 ET · Announcements

TenX Keane Acquisition Announces Contribution to Trust Account in Connection With Extension Amendment Proposal

New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR)) (the "Company"), announced today that if the proposal to amend the Company's Amended and Restated Memorandum and

GlobeNewswireJan 10 14:29 ET

Citius Unit to Merge With TenX Keane to Form Public Company

Seeking AlphaOct 24, 2023 09:23 ET

Citius' Oncology Unit to Go Public Via SPAC Merger

By Dean Seal Citius Pharmaceuticals has signed a deal to merge its oncology-focused subsidiary with the blank-check company TenX Keane Acquisition and have the business become its own public company.

Dow JonesOct 24, 2023 07:46 ET

TenX Keane Acquisition Halted, News Pending

InvestingOct 24, 2023 07:34 ET